RE:RE:RE:Insiders..Joseph Arena purchased 2,500 shares at $1.97 US. Dawn Svoronos exercised 50,000 options early when the stock had dropped below $2/share and didn't sell those shares. There would be tax consequences to exercising the options early, and because she exercised early, it would appear she felt the stock was cheap and therefore better to pay the tax early rather than a higher tax later on any increase in value. She hasn't sold those shares yet. That's why I took these signals as positive and an insider nodd to something that was coming. Maybe they just thought the price was too cheap at the time and weren't anticipating any new news. We know they had to be anticipating those analyst research reports to be released after the fact, and they did generate a small increase in share value. That's also why this stock price drop and the pause had to have been a complete surprise. If they had known this pause was on the table, they would have had to have expected the stock price to drop if initiated. And it was, so while the amount of the drop isn't justified, THTX has sufferred from a lack of volume/interest and they would've known it wouldn't be good for the stock.
I just cannot imagine they thought the analyst reports would be the silver bullet to a higher stock price, but maybe they are that niave. They have not communicated enough to convince the market there is a real possibility of achieving these things, but we were beginning to see some evidence of a basis taking place. Now I have no idea where we are at. I'm confused. NASH seemed to be getting a lot of attention and a significant driver of the research reports. Why was that? Are we close to a positive announcement on NASH? There's no way the board was making there buying decisions on oncology with that surprise voluntary pause.
LouisW wrote: Who was buying recently? I cannot find the information...